JPWO2019204683A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019204683A5 JPWO2019204683A5 JP2020556863A JP2020556863A JPWO2019204683A5 JP WO2019204683 A5 JPWO2019204683 A5 JP WO2019204683A5 JP 2020556863 A JP2020556863 A JP 2020556863A JP 2020556863 A JP2020556863 A JP 2020556863A JP WO2019204683 A5 JPWO2019204683 A5 JP WO2019204683A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- tcr
- item
- sequence
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024056106A JP7761293B2 (ja) | 2018-04-19 | 2024-03-29 | Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862660083P | 2018-04-19 | 2018-04-19 | |
| US62/660,083 | 2018-04-19 | ||
| PCT/US2019/028239 WO2019204683A1 (en) | 2018-04-19 | 2019-04-19 | T cell receptors with mage-b2 specificity and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024056106A Division JP7761293B2 (ja) | 2018-04-19 | 2024-03-29 | Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021521776A JP2021521776A (ja) | 2021-08-30 |
| JP2021521776A5 JP2021521776A5 (https=) | 2022-03-03 |
| JPWO2019204683A5 true JPWO2019204683A5 (https=) | 2022-03-03 |
| JP7469807B2 JP7469807B2 (ja) | 2024-04-17 |
Family
ID=68239239
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556863A Active JP7469807B2 (ja) | 2018-04-19 | 2019-04-19 | Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用 |
| JP2024056106A Active JP7761293B2 (ja) | 2018-04-19 | 2024-03-29 | Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024056106A Active JP7761293B2 (ja) | 2018-04-19 | 2024-03-29 | Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12202877B2 (https=) |
| EP (1) | EP3784255B1 (https=) |
| JP (2) | JP7469807B2 (https=) |
| KR (1) | KR102892744B1 (https=) |
| CN (1) | CN112236447B (https=) |
| CA (1) | CA3097399A1 (https=) |
| WO (1) | WO2019204683A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102643923B1 (ko) | 2014-12-23 | 2024-03-05 | 이매틱스 바이오테크놀로지스 게엠베하 | 간세포 암종(hcc) 및 기타 암들에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합 |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| HUE058957T2 (hu) | 2016-12-08 | 2022-10-28 | Immatics Biotechnologies Gmbh | Új T-sejt receptorok és velük végzett immunterápia |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| KR20260017503A (ko) | 2020-02-14 | 2026-02-05 | 길리애드 사이언시즈, 인코포레이티드 | Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도 |
| CA3171370A1 (en) * | 2020-03-16 | 2021-09-23 | Ugur Sahin | Antigen-specific t cell receptors and t cell epitopes |
| US12312412B2 (en) | 2020-05-19 | 2025-05-27 | Amgen Inc. | MAGEB2 binding constructs |
| CN111718409B (zh) * | 2020-06-17 | 2021-03-02 | 深圳豪石生物科技有限公司 | 一种t细胞受体及其应用 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| JP2023549098A (ja) * | 2020-11-04 | 2023-11-22 | フェイト セラピューティクス，インコーポレイティド | 固形腫瘍を標的とする多重操作されたｉＰＳＣ及び免疫エフェクター細胞 |
| MX2023011690A (es) * | 2021-04-02 | 2023-12-15 | Amgen Inc | Construcciones de unión a mageb2. |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4452415B1 (en) | 2021-12-22 | 2026-02-25 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CA3253296A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Zinc Finger Degradation Agents of the Ikaros Family and Their Uses |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2651174A1 (en) | 2006-05-03 | 2007-11-15 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
| ES2635335T3 (es) | 2010-09-20 | 2017-10-03 | Biontech Cell & Gene Therapies Gmbh | Receptores de células T específicos de antígeno y epítopos de células T |
| CN103124740B (zh) | 2010-09-21 | 2015-09-02 | 美国卫生和人力服务部 | 抗-ssx-2t细胞受体和相关材料及使用方法 |
| WO2012054825A1 (en) * | 2010-10-22 | 2012-04-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mage-a3 t cell receptors and related materials and methods of use |
| ES2834070T3 (es) * | 2011-09-15 | 2021-06-16 | Us Health | Receptores de células T que reconocen MAGE restringido por HLA-A1 o HLA-Cw7 |
| IL286786B (en) | 2012-09-14 | 2022-09-01 | The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst | T cell receptors that recognize mhc mage–a3 are restricted type ii |
| US11834674B2 (en) | 2014-12-11 | 2023-12-05 | Riken | Modified immunocyte, method for producing modified immunocyte and utilization thereof |
| US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
| GB201603568D0 (en) * | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| CA3020555A1 (en) | 2016-04-08 | 2017-10-12 | Adaptimmune Limited | T cell receptors |
| KR20190059874A (ko) | 2016-04-08 | 2019-05-31 | 어댑티뮨 리미티드 | T 세포 수용체 |
| CA3035075A1 (en) * | 2016-09-23 | 2018-03-29 | Fred Hutchinson Cancer Research Center | Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof |
| GB201616238D0 (en) | 2016-09-23 | 2016-11-09 | Adaptimmune Ltd | Modified T cells |
| CN110139873A (zh) | 2016-10-03 | 2019-08-16 | 朱诺治疗学股份有限公司 | Hpv特异性结合分子 |
| DE102016123859B3 (de) | 2016-12-08 | 2018-03-01 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| WO2018162563A1 (en) * | 2017-03-07 | 2018-09-13 | Universität Basel | Mr1 restricted t cell receptors for cancer immunotherapy |
| AU2018318303A1 (en) * | 2017-08-18 | 2020-04-09 | Gritstone Bio, Inc. | Antigen-binding proteins targeting shared antigens |
-
2019
- 2019-04-19 CN CN201980037254.1A patent/CN112236447B/zh active Active
- 2019-04-19 WO PCT/US2019/028239 patent/WO2019204683A1/en not_active Ceased
- 2019-04-19 JP JP2020556863A patent/JP7469807B2/ja active Active
- 2019-04-19 EP EP19787925.7A patent/EP3784255B1/en active Active
- 2019-04-19 US US17/048,748 patent/US12202877B2/en active Active
- 2019-04-19 CA CA3097399A patent/CA3097399A1/en active Pending
- 2019-04-19 KR KR1020207031165A patent/KR102892744B1/ko active Active
-
2024
- 2024-03-29 JP JP2024056106A patent/JP7761293B2/ja active Active
- 2024-12-09 US US18/973,614 patent/US20250101079A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521776A5 (https=) | ||
| JPWO2019204683A5 (https=) | ||
| US20250171560A1 (en) | Chimeric antigen receptor cells for treating solid tumor | |
| Daver et al. | T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments | |
| EP3946621B1 (en) | Mage a4 t cell receptors | |
| US10561686B2 (en) | Modified cell expansion and uses thereof | |
| TWI826891B (zh) | 轉染 t 細胞和 t 細胞受體用於癌症免疫治療 | |
| EP4274586A1 (en) | Car cells and polyspecific binding molecules for treating solid tumor | |
| US20190119350A1 (en) | Ny-eso-1 specific tcrs and methods of use thereof | |
| US20210379149A1 (en) | Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy | |
| US20180223255A1 (en) | Activation and Expansion of T Cells | |
| RU2018135097A (ru) | Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине | |
| US11161913B2 (en) | Chimeric antigen receptor cells for treating solid tumor | |
| US11008556B2 (en) | Chimeric antigen receptor (CAR) and T cell receptor (TCR) modified T cells | |
| US20200392247A1 (en) | T cell-antigen coupler with y182t mutation and methods and uses thereof | |
| Geiger et al. | New approaches for the immunotherapy of acute myeloid leukemia | |
| US20240199760A1 (en) | Nanobody Target MSLN and Uses in Chimeric Antigen Receptor Cell Therapy | |
| US20240269182A1 (en) | Modified Chimeric Antigen Receptor and Use thereof | |
| CN113929767A (zh) | 具有高亲和力的t细胞受体及其用途 | |
| AU2019327490B2 (en) | Chimeric antigen receptor cells for treating solid tumor | |
| US20260055209A1 (en) | Nanobody Target GCC and Uses in Chimeric Antigen Receptor Cell Therapy | |
| CN101100666B (zh) | 人TCRVβ7.1_H3F7基因及其筛选方法和应用 | |
| Subklewe | Current status of immunotherapy in acute myeloid leukemia | |
| JPWO2021237068A5 (https=) | ||
| WO2024243807A1 (zh) | 靶向ny-eso-1的高亲和力t细胞受体及其应用 |